ARMATA PHARMACEUTICALS, INC. Proceeds from Issuance or Sale of Equity
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Proceeds from Issuance or Sale of Equity of $12.25 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-25.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOrSaleOfEquity · last filed 2019-05-06
- ARMATA PHARMACEUTICALS, INC. proceeds from issuance or sale of equity for fiscal 2018 was $12.25M, a 30.95% increase from fiscal 2017.
- ARMATA PHARMACEUTICALS, INC. proceeds from issuance or sale of equity for fiscal 2017 was $9.35M, a 23.62% increase from fiscal 2016.
- ARMATA PHARMACEUTICALS, INC. proceeds from issuance or sale of equity for fiscal 2016 was $7.57M, a 38.91% decline from fiscal 2015.
- ARMATA PHARMACEUTICALS, INC. proceeds from issuance or sale of equity for fiscal 2015 was $12.38M.
| Period end | Proceeds from Issuance or Sale of Equity | Proceeds from Issuance or Sale of Equity 12 month |
|---|---|---|
| 2018-12-31 | $12.25M 10-K · filed 2019-03-25 | |
| 2018-03-22 | $2.80M 10-Q · filed 2019-05-06 | |
| 2018-01-12 | $3.40M 10-Q · filed 2019-05-06 | |
| 2017-12-31 | $9.35M 10-K · filed 2019-03-25 | |
| 2017-05-10 | $9.40M 10-Q · filed 2018-11-08 | |
| 2016-12-31 | $7.57M 10-K · filed 2018-03-14 | |
| 2015-12-31 | $12.38M 10-K · filed 2017-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |